Agoracom Blog Home

Posts Tagged ‘Hemp’

« Older Entries
Newer Entries »

Hollister Biosciences $HOLL.ca Announces DTC Eligibility $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 6:51 AM on Tuesday, April 14th, 2020
  • Shares are now eligible for electronic clearing and settlement in the United States through the Depository Trust Company
  • DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies

VANCOUVER, April 14, 2020 – Hollister Biosciences Inc. (CSE: HOLL, FRANKFURT: HOB, OTC: HSTRF) (the “Company” or “Hollister“), is pleased to announce that its shares are now eligible for electronic clearing and settlement in the United States through the Depository Trust Company (“DTC“).  DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies.  DTC services provide cost benefits for investors and brokers trading Canadian securities in the United States.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a diversified cannabis company with multiple, high-quality products now carried in 220 of Indus Holdings (CSE: INDS), Hollister’s exclusive distribution partner’s 600 dispensaries. This level of penetration is expected to grow as the Company accelerates its seed to shelf, high margin business and product development model.

Capitalizing on this success, Hollister’s vision is to become the sought-after premium brand portfolio of innovative, high quality cannabis across multiple states and hemp products nationwide.

Our wholly owned California subsidiary, Hollister Cannabis Co, is the 1st state and locally licensed Cannabis Company in the City of Hollister, California, the birthplace of the “American Biker” from which we embrace the outlaw roots of Hollister to drive our Company fearlessly down the road of success.

Products from Hollister Cannabis Co. include HashBone, the brand’s premier artisanal hash-infused pre-roll ranked as California’s #1 hash infused pre-roll, along with solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures.

Website: www.hollistercannabisco.com

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

Tags: , , ,
Posted in Hollister Biosciences | Comments Off on Hollister Biosciences $HOLL.ca Announces DTC Eligibility $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Cannabis sales spike after lockdown measures in legalised areas – SPONSOR: Spyder #Cannabis $SPDR.ca – $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 12:37 PM on Monday, April 13th, 2020

SPONSOR: Spyder Cannabis (SPDR:TSXV) An established chain of high-end vape stores. Aggressive expansion plan is already in place that will focus on Canadian retail and US Hemp derived kiosks in high traffic areas. Click here for more info.

Cannabis sales spike after lockdown measures in legalised areas

  • As more people are confined to their homes, and can’t get out to unwind in other ways, they bought cannabis products at higher rates, and in bigger amounts than they have before

by Sanjana Varghese

Around the world, precautions against the spread of coronavirus have meant that people are confined to their homes for a while. Everyone has their own plans, which has included stockpiling loo roll, food and medicine. 

For people who realise that they may want to relax, those preparations include stockpiling cannabis too – in Canada, the Netherlands, and states in the US where cannabis is legal to buy, the coronavirus lockdown has caused a surge in demand for cannabis products, particularly online and at dispensaries. 

As more people are confined to their homes, and can’t get out to unwind in other ways, they bought cannabis products at higher rates, and in bigger amounts than they have before.

Now that lockdown measures have been in place for several weeks, cannabis companies and other retailers have been able to take stock of how their businesses have fared.

In the middle of March, several marijuana businesses throughout the US saw a spike in people buying all kinds of products. People also tended to be buying it in larger quantities than they would normally.

In California, sales had gone up 159 per cent compared to the sales in March of 2019. 

In general, the legal cannabis industry is a growing one, so there will be more people buying it “officially” than the year before. Even so, the kind of spike that cannabis business owners around the world saw in mid-March coincided exactly with announcements of cannabis lockdowns.  

But is this a good thing? Information from the World Health Organisation suggests that smoking cannabis can weaken the lungs, which isn’t a good thing when we have a global pandemic of a virus which attacks the respiratory system.

However, it seems people may have thought of this.

Data from Headset suggests that while sales of cannabis were up 10 per cent, edibles surged in demand too – by 28 per cent – and that people are shifting away from pre-rolled products when thinking about what they would want to stock up on for a few weeks. 

In Ontario, Canada there were almost 3,000 orders on the last Saturday before full lockdown at the Ontario Cannabis Store. That was an 80 per cent increase over a typical Saturday.  

Daffyd Roderick, the communications director at the OCS, said that they had seen a significant increase in demand for same-day and next day delivery options, in addition to a higher volume of purchases.

Other cannabis stores, in the province of Quebec, also said that they had seen a spike in sales of cannabis over the weekend. Additionally, many shops have started to operate a click and collect service – where people can come and pick up their orders themselves. These kinds of services could offer a chance for people to keep stocked up on the products they want, but they minimise social contact as much as possible. Measures like this are possible in Canada, where individual provinces maintain a monopoly on the sales of cannabis – so they can implement changes more quickly than elsewhere.

In the Netherlands, photos circulated on social media of people in towns and cities lining up to buy cannabis and weed from coffee shops before a government-imposed quarantine would put the country on lockdown. 

While cannabis is illegal in the Netherlands, it is decriminalised for personal use, and posts from social media users showed lines of more than 20 or 30 people waiting to stock up in various cities, from Amsterdam to Utrecht.

The day after the announcement was made, cafes and coffee shops were allowed to re-open as long as they were only offering takeaway services. 

The situation around cannabis in the US is different from places like Canada and the Netherlands because federal policy governs whether cannabis is legal, as well as whether there are other restrictions on what dispensaries can do with their stock. In eight states that have imposed stay-at-home orders, recreational cannabis can still be sold, and over 15 others have continued to allow the sale of medical cannabis only. 

In states like California and Washington, dispensaries have reported huge increases in demand for their products since mid March.

In Oakland, a dispensary’s whole supply was sold out by 2pm on the day that the lockdown measures were announced.

Delivery services in San Francisco said they had seen an increase in demand for cannabis delivery too, although they weren’t as severe as recent spikes. 

In Pennsylvania, Governor Tom Wolfe declared marijuana dispensaries an essential business, which brought in changes that had otherwise been passing slowly through legislation. Telemedicine – where people are prescribed medication over the phone – mean cannabis has become much more accessible, and for people who needed cannabis to treat illnesses or reduce their symptoms, getting the adequate documentation happened much more quickly too.

Some dispensaries have also transitioned to offering drive-through services too, to minimise contact. 

Other elements of the legal cannabis industry have changed in response to Covid-19. 

The government in Oregon increased the minimum amount of cannabis that you could buy in one go, to stop people from making more trips.

Websites like Leafly, which focus on the world of cannabis, have created guides on disinfecting cannabis product packaging and taking other safety precautions. For business owners, it’s an opportunity to strengthen online vendor systems and figure out whether a drive through system is possible. 

As lockdown measures are extended around the world, cannabis business owners are attempting to figure out what they should be doing next – in some cases, they ordered in extra stock and increased hours for workers. In others, they’ve been encouraging customers to place their orders online, rather than coming into town.

Currently, the length of the lockdown measures remains uncertain, so you might as well be well prepared, whether you’re buying or selling.

Source: https://www.indy100.com/article/coronavirus-cannabis-marijuana-sales-legal-lockdown-9459851

Tags: , , , , , ,
Posted in Spyder Cannabis Inc. | Comments Off on Cannabis sales spike after lockdown measures in legalised areas – SPONSOR: Spyder #Cannabis $SPDR.ca – $CGC $ACB $APH $CRON.ca $OGI.ca

Where is the #CBD Market Headed? – SPONSOR: Hollister Biosciences $HOLL.ca $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 5:52 PM on Thursday, April 9th, 2020

SPONSOR: Hollister Biosciences Inc. (HOLL:CSE) A vertically integrated cannabis company with products in 220 California dispensaries and joint ventures, licensing agreement & partnerships with global brands. The company recently closed $20 MILLION deal with Venom Extracts adding $CDN 16.4 million in revenue and $CDN 2.48 million in EBITDA. Learn More

Where is the CBD Market Headed?

  • After hemp was legalized for growth and cultivation with the passing of new legislation in 2018, the CBD market erupted with new products and companies looking to take advantage of the new space
  • As of 2019, CBD sales increased by around 133%, to the tune of over $1 billion. That’s right; one billion. The market has plenty of consumer demand to back it up, and Americans are loving their CBD

By: Guest Contributor

With the last few years’ success in the CBD industry, new investors, everyday people, and seasoned investors alike are working to get their hands into one of the fastest-growing markets in the US. The CBD space is full of new providers and products, and new ones are arising each year.

As the research receives more and more funding, we’re learning all kinds of new information about CBD and its effects on the body and mind; and not much of that information is negative.

With so much demand for CBD oil and other products, it’s no surprise that people are looking to get rich by investing in the industry. But there’s still the question of whether or not it’s a good idea to invest in CBD. Let’s take a closer look at the industry, so you can decide whether or not investing in it is the right move for you.

CBD’s Benefits and Popularity

For decades, the Cannabis plant, from which CBD is derived, was outlawed, shamed, and viewed as an addictive and dangerous drug. This is mostly because THC is also derived from Cannabis, which causes the “high” that comes with smoking marijuana or ingesting THC-infused oils and edibles.

CBD is an entirely different cannabinoid, and both CBD and THC are just two of many cannabinoids found in the Cannabis plant. Each cannabinoid interacts with the body’s cannabinoid receptors in a different way, but it would take another article entirely to explain them all.

The bottom line? CBD doesn’t get you high, and industrial hemp must contain less than 0.3% THC to even be legally grown or cultivated.

CBD has been found to offer many benefits to humans and pets alike; among these are:

  • Pain relief
  • Anti-inflammatory properties
  • Counteracts the effects of THC
  • Useful in addiction recovery
  • Managing anxiety disorders and stress
  • Calming effects on the brain
  • Increase focus and concentration

The benefits of CBD products far outweigh the minor side effects, and preliminary research has yielded promising results for the future of CBD. If you want to buy CBD to give it a try, you’ve chosen the right time to start! There are hundreds of varieties available, but not all CBD is created equal.
Quality Matters in CBD

If you’re thinking of investing in the CBD space, you’ll want to put your money towards a product that exceeds others in terms of quality. The higher the quality of the CBD extract, the more potent it is.

Lower-quality extracts aren’t as effective, and if the producer is using imported hemp, you run the risk of contaminating your CBD with pesticides and other chemicals from foreign countries. The US has some strict guidelines on growing hemp, and the top providers in the industry use only organically-grown domestic hemp to extract their CBD.

The Market So Far

After hemp was legalized for growth and cultivation with the passing of new legislation in 2018, the CBD market erupted with new products and companies looking to take advantage of the new space. As of 2019, CBD sales increased by around 133%, to the tune of over $1 billion. That’s right; one billion. The market has plenty of consumer demand to back it up, and Americans are loving their CBD.

Some estimates put the market at around $20 billion by 2022, but more conservative estimates put it somewhere around half that. It’s estimated that by 2024, the market will be worth $10 billion, and that’s not something investors can ignore.

The demand for CBD products only continues to increase as the years go by, so at this point, the only way to know for sure where CBD is headed is to wait and see.

That being said, the market shows potential for growth and continues to gain traction as more and more people try and love CBD products. This makes for an excellent investment opportunity if you know what you’re doing and where to put your money.

Among specialized dispensaries, even general retailers are starting to carry CBD. You may have noticed your local grocery stores, department stores, and even convenience stores carrying CBD oil and other CBD products.

This surge in CBD availability does present an issue, however; the producers are struggling to keep up.

The Quick-Buck Types

As with any industry, there are those looking to make a quick buck by ignoring quality standards and putting out a sub-par product just to get it on the shelves and into the hands of paying customers.

With little regulation on CBD products from government agencies, the standards in the industry are generally set by the top providers, and can’t exactly be enforced.

This leads to general flooding of the market with sub-par products, and many of those “off brands” end up on store shelves as retailers try to get their hand in the CBD market. Many CBD providers are working very hard to ensure their products meet certain standards, and those are the companies you’ll want to keep your eye on.

Where To Next?

The market seems to only be headed upward as time passes. With more money for research and much less stigma surrounding CBD and cannabis, there is the potential for massive growth as the public slowly shifts its opinion on the plant itself. With projections in the billions of dollars for the future, it’s safe to say that this market has a bright future ahead of it.

Not to mention, the better we understand CBD, the better it can be marketed. We’ve already found dozens of incredible benefits for the human body, and we’re sure to find more as our understanding of CBD evolves. We just have to be patient and wait for the research!

In the meantime, the market is flourishing and is expected to flourish well into the 2020 decade. If you’re looking to invest your money in a market that can offer significant ROI and stability, CBD might just be it. Always consult with an expert first, though. You wouldn’t want to put your money into the wrong startup!

Source: https://www.bigeasymagazine.com/2020/04/06/where-is-the-cbd-market-headed/

Tags: , , , ,
Posted in All Recent Posts, Hollister Biosciences | Comments Off on Where is the #CBD Market Headed? – SPONSOR: Hollister Biosciences $HOLL.ca $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

#CBD #Edibles Market to Exhibit an Astonishing CAGR of 24.30% – SPONSOR: Hollister Biosciences $HOLL.ca $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 6:00 PM on Wednesday, April 8th, 2020

SPONSOR: Hollister Biosciences Inc. (HOLL:CSE) A vertically integrated cannabis company with products in 220 California dispensaries and joint ventures, licensing agreement & partnerships with global brands. The company recently closed $20 MILLION deal with Venom Extracts adding $CDN 16.4 million In revenue and $CDN 2.48 million in EBITDA. FIND OUT MORE

CBD Edibles Market to Exhibit an Astonishing CAGR of 24.30%

  • Data Bridge Market Research analyses the market to account to USD 5160 million by 2027 growing at a CAGR of 24.30% in the forecast period
  • Rising global healthcare spending is expected to enhance the market growth

By Data Bridge Market Research

The CBD Edibles Market report comprehensively studies market definition, market segmentation, competitive analysis and key developments in the market. It comprises of fundamental, secondary and advanced information related to the global status and trend, market size, sales volume, market share, growth, future trends analysis, segment and forecasts from 2020 – 2027. It includes an extensive research on the current conditions of the industry, potential of the market in the present and the future prospects from various angles. Thus, the transparent, reliable and extensive market information of this CBD Edibles report will definitely develop business and improve return on investment (ROI).

Data Bridge Market Research analyses the market to account to USD 5160 million by 2027 growing at a CAGR of 24.30% in the forecast period. Rising global healthcare spending is expected to enhance the market growth.

An Overview of the Impact of COVID-19 on Particular Market:                   

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

CBD Edibles Market Overview 2020-2027: Some of the factors such as rising production of hemp, increasing awareness about the health advantages of cannabis, rising demand from the healthcare industry, and legalization of cannabis in the various industries is expected to enhance the CBD edibles market in the forecast period of 2020 to 2027. High cost of the CBD products and presence of stringent regulations is expected to hamper the market growth in the mentioned forecast period.

Global CBD Edibles Market Scope and Market Size

CBD edibles market is segmented of the basis of source type and application. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

o Based on source type, the CBD edibles market is bifurcated into hemp and marijuana.

o The application segment of the CBD edibles market is segmented into personal care & cosmetics, pharmaceutical, food & beverage and others.

The Global CBD Edibles Market 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The market Report also calculate the market size, the report considers the revenue generated from the sales of This Report and technologies by various application segments. The data and the information regarding the CBD Edibles industry are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the market experts.

Global CBD Edibles Industry 2020 Market Research Report is spread across 350 pages and provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Source: https://sciencein.me/2020/04/08/cbd-edibles-market-to-exhibit-an-astonishing-cagr-of-24-30-industry-size-share-demand-growth-segmentation-and-future-insights-2020-2027/

Tags: , , , , ,
Posted in All Recent Posts, Hollister Biosciences | Comments Off on #CBD #Edibles Market to Exhibit an Astonishing CAGR of 24.30% – SPONSOR: Hollister Biosciences $HOLL.ca $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Mota Ventures $MOTA.ca Acquires Interest in Folium Life Sciences $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 8:25 AM on Wednesday, April 8th, 2020
Mota large
  • Folium is a Health Canada licensed cannabis cultivator with facilities located on Vancouver Island.
  • Folium is nearing completion of the expansion of its existing cultivation facility, a further phase 2 expansion of the facility is expected.

VANCOUVER, BC / April 8, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTCPINK:PEMTF) (the “Company“) is pleased to announce that it has acquired (the “Acquisition“) all of the outstanding share capital of 1244780 B.C. Ltd. (the “Target“). The Acquisition was completed pursuant to a share exchange agreement (the “Purchase Agreement“), dated April 7, 2020, and entered into with an arms-length third-party (the “Vendor“). The sole asset of the Target consists of a 20% equity interest in Folium Life Sciences Inc. (“Folium“), which is in the process of developing a licensed indoor cannabis production facility located on Vancouver Island. In consideration for the Acquisition, the Company has issued 21,000,000 common shares.

Folium is a Health Canada licensed cannabis cultivator with facilities located on Vancouver Island. Folium is nearing completion of the expansion of its existing cultivation facility. Its business plan calls for a further phase 2 expansion of the facility. Folium aims to produce a high quality and consistent cannabis product through its facilities.

“Canada has been a pioneer in legalization and early adoption of cannabis for both recreational and medical purposes. This equity position in a well-capitalized licensed producer provides Mota with a sound financial investment in the sector.” stated Ryan Hoggan, CEO of the Company.

Each of the Vendor, the Target, and Folium are at arms-length from the Company. The Acquisition does not constitute a fundamental change for the Company, nor has it resulted in a change of control of the Company within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. In connection with completion of the Acquisition, the Company has issued 210,000 common shares (the “Administrative Fee Shares“) to a consultant who assisted with the Acquisition.

About Mota Ventures Corp.

Mota Ventures is seeking to become a vertically integrated global CBD brand. Its plan is to cultivate and extract CBD into high-quality value-added products from its Latin American operations and distribute it both domestically and internationally. Its existing operations in Colombia consist of a 2.5-hectare site that has optimal year-round growing conditions and access to all necessary infrastructure. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Joel Shacker
President

For further information, readers are encouraged to contact Joel Shacker, President, at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Tags: , , , , , , , , , , ,
Posted in All Recent Posts, Mota Ventures Corp. | Comments Off on Mota Ventures $MOTA.ca Acquires Interest in Folium Life Sciences $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Cannabis Expo London 2020 – Experience the Europe Canna Expo SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 4:36 PM on Monday, April 6th, 2020

SPONSOR: Mota is seeking to become a vertically integrated global CBD brand. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota. Combined total sales of almost $29,000,000 with a EBITDA of approximately 12.5% (2019) . Click Here for More Info

Mota large

With the current climate of social distancing and uncertainty, it’s no surprise that events have been forced to cancel or postpone left, right, and centre. Despite the disruption caused by the Coronavirus pandemic, some organisers are persevering with their plans – at least for the time being. One of those events is the Europe Canna Expo, set to take place in  London in July.

The Europe Canna Expo (ECE) is scheduled to make a return to London for a 2-day event on 26-27 July. Following the success of last year’s Europe CBD expo at the same location, the ECE will aim to bring together over 90 speakers and 125 exhibitors.

The Venue

The ECE is set to make a return to the London ExCel Centre in Canning Town East London. The event was held at the venue in July 2019, with an array of exhibitors and speakers. This year, the Europe Canna Expo is expected to be even bigger. However, uncertainty remains over the event.

The ExCel Centre is currently home to the temporary Nightingale hospital – the improvised care centre for victims of the Coronavirus. It remains unclear when the need for the venue will be over as the UK’s Coronavirus lockdown continues.

Exhibitors and Speakers

However, should the expo go on as planned, attendees will be spoilt for choice with speakers and professionals set to provide insights into the CBD, cannabinoid, and medical cannabis industries. In addition, the event will be present a huge number of exhibitors including a variety of manufacturers and businesses.

Speakers will include international experts showcasing senior-level insights and global scientific research in the CBD, cannabinoid and medical cannabis sectors. Organisers of the event expect that attendees will include consumers and businesses, as well as policymakers and press.

The event will provide an opportunity for global leading brands to showcase their products to thousands of attendees. From CBD drinks and chocolates to medicinal products, the Europe Canna Expo plans to present the most innovative international brands.

Event Schedule

The ECE organisers are yet to release a detailed schedule for the two-day cannabis expo. This may be due to the ongoing uncertainty surrounding the Coronavirus lockdown. For more information and up-to-date announcements, visit the ECE London website.

https://canex.co.uk/cannabis-expo-2020-europe-canna-expo-london/

Tags: , , , , , , , , , , ,
Posted in All Recent Posts, Mota Ventures Corp. | Comments Off on Cannabis Expo London 2020 – Experience the Europe Canna Expo SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Mota Ventures $MOTA.ca Acquires Over 20,000 Customers in March, Launches New Immune Support Product Line $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 9:13 PM on Sunday, April 5th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/Mota-Square-Logo-For-Blog-3.jpg
  • Immune Support product line has been received exceptionally well by consumers
  • The total number of customers acquired by First Class CBD in March 2020 is 20,959, including 6,419 immune customers
  • Initial average spend of Cdn$218.40 per customer

VANCOUVER, BC / April 4, 2020 Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC:PEMTF) (the “Company” or “Mota“) is pleased to provide an update on the recent progress that is fueling the increase in sales for products under its First Class CBD brand. The Immune Support product line has been received exceptionally well by consumers since it launched on March 14, 2020 and has been a significant driver of growth in March. The total number of customers acquired by First Class CBD in March 2020 is 20,959, including 6,419 immune customers with an initial average spend of Cdn$218.40 per customer.

The Company will be launching a new brand, Nature’s Exclusive CBD on April 6, 2020. The new Nature’s Exclusive CBD brand will introduce a line of Immune Support and CBD products with a higher content of CBD. The Company also anticipates releasing March 2020 financial results for First Class CBD in the next few days.

“The month of March has been exceptional, with new customer signups exceeding expectations. We believe this is a testament to our ability to adapt to the fast-paced eCommerce sector and ability to identify upcoming trends in consumer demand. I am very excited with the rapid progress and look forward to releasing March results in the upcoming days,” stated Ryan Hoggan, CEO of the Company.

The initial average spend per customer was translated from US dollar into Canadian dollar using the Bank of Canada average exchange rate of 1.3953 for March 2020.

About Mota Ventures Corp.

Mota is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its First Class CBD and Nature’s Exclusive brands. Within Europe, its Satavida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.
Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President, at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Tags: , , , , , , , , ,
Posted in All Recent Posts, Mota Ventures Corp. | Comments Off on Mota Ventures $MOTA.ca Acquires Over 20,000 Customers in March, Launches New Immune Support Product Line $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

INTERVIEW: Empower $CBDT.ca #CBD Clinics Visits Climb By 478% In Q1 As #Coronavirus Stress Drives Demand For CBD $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:41 PM on Sunday, April 5th, 2020

With 165,000 patients, Empower Clinics (CBDT:CSE) (EPWCF:OTCQB) has a database that almost every medical cannabis and CBD company would kill for.  Patient visits increased 800% in February. 590% in March and 480% for Q1.  But will Coronavirus social gathering imitations put the clinic network at risk?

No.  In fact, it has had the opposite effect, with the clinics being designated an essential service.  Moreover, Empower has had to actually increase operating hours due to demand from existing patients who need their CBD medication more than ever, as well as, new patients who are experiencing anxiety and stress through the COVID-19 pandemic.  

Moreover, the Company has also  entered expanded into telemedicine across multiple states for patients who can’t get to a clinic but need a consultation with doctors over the phone to determine the best CBD medications for home delivery.

Watch this interview with the Company’s CEO, Steven McAuley, who is Six Sigma certified under the quality initiative of legendary GE chairman Jack Welch. We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never …. which also explains how McAuley has been able to guide Empower Clinics through the most disruptive retail environment in recent history.  

Grab your favourite beverage and settle in to watch what may be your next great small cap investment

Tags: , , , , , ,
Posted in Empower Clinics Inc., Featured | Comments Off on INTERVIEW: Empower $CBDT.ca #CBD Clinics Visits Climb By 478% In Q1 As #Coronavirus Stress Drives Demand For CBD $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Mota Ventures $MOTA.ca Acquires Over 20,000 Customers in March, Launches New Immune Support Product Line $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM-JC at 12:19 PM on Saturday, April 4th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/Mota-Square-Logo-For-Blog-3.jpg
  • Immune Support product line has been received exceptionally well by consumers
  • The total number of customers acquired by First Class CBD in March 2020 is 20,959, including 6,419 immune customers
  • Initial average spend of Cdn$218.40 per customer

VANCOUVER, BC / April 4, 2020 Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC:PEMTF) (the “Company” or “Mota“) is pleased to provide an update on the recent progress that is fueling the increase in sales for products under its First Class CBD brand. The Immune Support product line has been received exceptionally well by consumers since it launched on March 14, 2020 and has been a significant driver of growth in March. The total number of customers acquired by First Class CBD in March 2020 is 20,959, including 6,419 immune customers with an initial average spend of Cdn$218.40 per customer.

The Company will be launching a new brand, Nature’s Exclusive CBD on April 6, 2020. The new Nature’s Exclusive CBD brand will introduce a line of Immune Support and CBD products with a higher content of CBD. The Company also anticipates releasing March 2020 financial results for First Class CBD in the next few days.

“The month of March has been exceptional, with new customer signups exceeding expectations. We believe this is a testament to our ability to adapt to the fast-paced eCommerce sector and ability to identify upcoming trends in consumer demand. I am very excited with the rapid progress and look forward to releasing March results in the upcoming days,” stated Ryan Hoggan, CEO of the Company.

The initial average spend per customer was translated from US dollar into Canadian dollar using the Bank of Canada average exchange rate of 1.3953 for March 2020.

About Mota Ventures Corp.

Mota is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its First Class CBD and Nature’s Exclusive brands. Within Europe, its Satavida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.
Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President, at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the anticipated launch of products under the First Class CBD brand, the financial results of First Class CBD, its plans to become a vertically integrated global CBD brand, its plans to cultivate and extract cannabis to produce CBD and high-quality value added CBD products in Latin America for distribution domestically and internationally. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Tags: , , , , , , , , ,
Posted in Featured, Mota Ventures Corp. | Comments Off on Mota Ventures $MOTA.ca Acquires Over 20,000 Customers in March, Launches New Immune Support Product Line $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Primo Nutraceuticals Inc., $PRMO.ca Signs Share Acquisition LOI with Celebrity brand Beauty Kitchen $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 3:03 PM on Friday, April 3rd, 2020
  • Company has signed a non-binding letter of intent with Heather Marianna, LLC, doing business as Beauty Kitchen
  • The LOI is non-binding and subject to possible change and the signing of a definitive agreement

VANCOUVER, British Columbia, April 03, 2020 — PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“Primo” or the “Company”)Pursuant to discussions with IIROC (Investment Industry Regulatory Organization of Canada) Primo’s board and management team are providing more clarity to its shareholders in regards to the press release issued on March 31st, 2020.

The Company has signed a non-binding letter of intent (LOI) with Heather Marianna, LLC, doing business as Beauty Kitchen, a Nevada company, (“Beauty Kitchen”).  The LOI is non-binding and subject to possible change and the signing of a definitive agreement.

Primo and Beauty Kitchen intend to draft and execute a definitive agreement (the “Definitive Agreement”) with detailed terms and conditions in the near future.  Beauty Kitchen intends to incorporate a Canadian corporation, Marianna, Inc., (“Marianna, Inc.”) in which it will conduct operations in Canada. Primo will acquire an ownership interest of 25% of the common voting (TBC) shares in Marianna, Inc., for consideration to be determined in the Definitive Agreement. Primo wishes to inform its shareholders that the transaction described by the LOI is subject to change pending signing of the Definitive Agreement.

On behalf of the Board of Directors

PRIMO NUTRACEUTICALS INC.

“Andy Jagpal”

President and Director

For further information, please contact Zoltan, IR Representative at: 604-722-0305, or; [email protected].

To learn more about what this news means to the shareholders visit:

www.primonutraceuticals.com
www.twitter.com/Prmoinc
www.thrivecbd.com
www.beautykitchenonline.com

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
No regulatory authority has approved or disapproved the information contained in this news release.

Tags: , , , , , ,
Posted in PRIMO Nutraceuticals Inc. | Comments Off on Primo Nutraceuticals Inc., $PRMO.ca Signs Share Acquisition LOI with Celebrity brand Beauty Kitchen $CROP.ca $VP.ca NF.ca $MCOA

« Older Entries
Newer Entries »